Raymond T. Bartus
Raymond T. Bartus has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
Dwaine F. Emerich
Alkermes, Inc, Cambridge, Massachusetts 02139, USA
5 shared publicationsReginald L. Dean
Alkermes, Inc
4 shared publicationsPamela Snodgrass
Alkermes, Inc
3 shared publicationsJoanne Marsh
Alkermes, Inc
2 shared publicationsAlexis Perkins
1 shared publicationBrigido Perdomo
Alkermes, Inc
1 shared publication
Latest Publications
- 1 July 2002
- Published by Springer Nature in Pharmaceutical Research
- Vol. 19 (7) , 1052-1060
Sustained Release Chemotherapeutic Microspheres Provide Superior Efficacy over Systemic Therapy and Local Bolus Infusions
Purpose.The present studies evaluated the ability of injectable, biodegradable microspheres releasing carboplatin, doxorubicin, or 5-fluorouracil to suppress the growth of solid tumors implanted...
- 1 July 2002
- Published by Springer Nature in Pharmaceutical Research
- Vol. 19 (7) , 1052-1060
Sustained Release Chemotherapeutic Microspheres Provide Superior Efficacy over Systemic Therapy and Local Bolus Infusions
Purpose.The present studies evaluated the ability of injectable, biodegradable microspheres releasing carboplatin, doxorubicin, or 5-fluorouracil to suppress the growth of solid tumors implanted...
- 1 January 2001
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 40 (2) , 105-123
The Development of the Bradykinin Agonist Labradimil as a Means to Increase the Permeability of the Blood-Brain Barrier
Labradimil (Cereport®; also formerly referred to as RMP-7) is a 9-amino-acid peptide designed for selectivity for the bradykinin B2 receptor and a longer plasma half-life than bradykinin. It has been developed to increase the permeability of the blood-brain barrier (BBB) and is the first compound with selective bradykinin B2 receptor agonist properties to progress from concept design through to tests of efficacy in patients. In vitro studies demonstrate that labradimil has a longer half-life than bradykinin and selectively binds to bradykinin B2 receptors, initiating typical bradykinin-like second messenger systems, including increases in intracellular calcium and phosphatidylinositol turnover. Initial proof of principle studies using electron microscopy demonstrated that intravenous labradimil increases the permeability of the BBB by disengaging the tight junctions of the endothelial cells that comprise the BBB. Autoradiographic studies in rat models further demonstrated that labradimil increases the permeability of the BBB in gliomas. Intravenous or intra-arterial labradimil increases the uptake of many different radiolabelled tracers and chemotherapeutic agents into the tumour in a dose-related fashion. These effects are selective for the tumour and for the brain surrounding the tumour, and are particularly robust in tumour areas that are normally relatively impermeable. The increased chemotherapeutic concentrations are maintained for at least 90 minutes, well beyond the transient effects on the BBB. The increase in permeability with labradimil occurs rapidly but is transient, in that restoration of the BBB occurs very rapidly (2 to 5 minutes) following cessation of infusion. Even with continuous infusion of labradimil, spontaneous restoration of the barrier begins to occur within 10 to 20 minutes. Collectively, these data demonstrate that the B2 receptor system that modulates permeability of the BBB is highly sensitive and autoregulated and that careful attention to the timing of labradimil and the chemotherapeutic agent is important to achieve maximal effects. Survival studies in rodent models of both gliomas and metastatic tumours in the brain demonstrate that the enhanced uptake observed with the combination of labradimil and water-soluble chemotherapeutics enhances survival to a greater extent than achieved with chemotherapy alone. Finally, preliminary clinical trials in patients with gliomas provide confirmatory evidence that labradimil permeabilises the blood-brain tumour barrier and might, therefore, be used to increase delivery of agents such as carboplatin to tumours without the toxicity typically associated with dose escalation.
- 1 January 2001
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 40 (2) , 105-123
The Development of the Bradykinin Agonist Labradimil as a Means to Increase the Permeability of the Blood-Brain Barrier
Labradimil (Cereport®; also formerly referred to as RMP-7) is a 9-amino-acid peptide designed for selectivity for the bradykinin B2 receptor and a longer plasma half-life than bradykinin. It has been developed to increase the permeability of the blood-brain barrier (BBB) and is the first compound with selective bradykinin B2 receptor agonist properties to progress from concept design through to tests of efficacy in patients. In vitro studies demonstrate that labradimil has a longer half-life than bradykinin and selectively binds to bradykinin B2 receptors, initiating typical bradykinin-like second messenger systems, including increases in intracellular calcium and phosphatidylinositol turnover. Initial proof of principle studies using electron microscopy demonstrated that intravenous labradimil increases the permeability of the BBB by disengaging the tight junctions of the endothelial cells that comprise the BBB. Autoradiographic studies in rat models further demonstrated that labradimil increases the permeability of the BBB in gliomas. Intravenous or intra-arterial labradimil increases the uptake of many different radiolabelled tracers and chemotherapeutic agents into the tumour in a dose-related fashion. These effects are selective for the tumour and for the brain surrounding the tumour, and are particularly robust in tumour areas that are normally relatively impermeable. The increased chemotherapeutic concentrations are maintained for at least 90 minutes, well beyond the transient effects on the BBB. The increase in permeability with labradimil occurs rapidly but is transient, in that restoration of the BBB occurs very rapidly (2 to 5 minutes) following cessation of infusion. Even with continuous infusion of labradimil, spontaneous restoration of the barrier begins to occur within 10 to 20 minutes. Collectively, these data demonstrate that the B2 receptor system that modulates permeability of the BBB is highly sensitive and autoregulated and that careful attention to the timing of labradimil and the chemotherapeutic agent is important to achieve maximal effects. Survival studies in rodent models of both gliomas and metastatic tumours in the brain demonstrate that the enhanced uptake observed with the combination of labradimil and water-soluble chemotherapeutics enhances survival to a greater extent than achieved with chemotherapy alone. Finally, preliminary clinical trials in patients with gliomas provide confirmatory evidence that labradimil permeabilises the blood-brain tumour barrier and might, therefore, be used to increase delivery of agents such as carboplatin to tumours without the toxicity typically associated with dose escalation.
- 1 March 1999
- Vol. 2 (2) , 152-67
The blood-brain barrier as a target for pharmacological modulation.
The blood-brain barrier (BBB) serves as an exquisitely controlled, functional gate to the central nervous system (CNS). It not only protects the brain from agents in the blood that could impair neurological function, but also controls the influx and efflux of numerous substances to maintain proper homeostasis and provide the brain with necessary nutrients that cannot be produced, de novo. Because the BBB also restricts the entry of many potentially therapeutically useful drugs, researchers have attempted to exploit systems that modulate the BBB in order to increase delivery of therapeutic agents into the brain. Two of the more prominent contemporary approaches are reviewed here. The first involves modulating the permeability of the BBB, focusing on stimulation of endogenous bradykinin receptors constituitively expressed on the endothelial cells of the BBB. The second approach is based on transport across the BBB, utilizing receptor-mediated systems that exist naturally to carry molecules into the brain. The endogenous iron/transferrin transport system has been used extensively preclinically to deliver intravenously administered nerve growth factor (NGF) to the brain and serves as the major focus for this discussion. The underlying principles, recent progress and issues associated with these alternative approaches to delivering therapeutic agents across the BBB are discussed.
- 1 March 1999
- Vol. 2 (2) , 152-67
The blood-brain barrier as a target for pharmacological modulation.
The blood-brain barrier (BBB) serves as an exquisitely controlled, functional gate to the central nervous system (CNS). It not only protects the brain from agents in the blood that could impair neurological function, but also controls the influx and efflux of numerous substances to maintain proper homeostasis and provide the brain with necessary nutrients that cannot be produced, de novo. Because the BBB also restricts the entry of many potentially therapeutically useful drugs, researchers have attempted to exploit systems that modulate the BBB in order to increase delivery of therapeutic agents into the brain. Two of the more prominent contemporary approaches are reviewed here. The first involves modulating the permeability of the BBB, focusing on stimulation of endogenous bradykinin receptors constituitively expressed on the endothelial cells of the BBB. The second approach is based on transport across the BBB, utilizing receptor-mediated systems that exist naturally to carry molecules into the brain. The endogenous iron/transferrin transport system has been used extensively preclinically to deliver intravenously administered nerve growth factor (NGF) to the brain and serves as the major focus for this discussion. The underlying principles, recent progress and issues associated with these alternative approaches to delivering therapeutic agents across the BBB are discussed.
- Open Access
- 1 January 1999
- Published by Taylor & Francis in Drug Delivery
- Vol. 6 (1) , 15-21
Use of CereportTM (RMP-7) to Increase Delivery of Carboplatin to Gliomas: Insight and Parameters for Intracarotid Infusion Via a Single-Lumen Cannula
CereportTM (RMP-7) is a selective bradykinin B receptor ago2 nist that increases the permeability of the blood-brain tumor barrier (BBTB) to increase delivery of chemotherapeutic agents to brain tumors. Two experiments were performed in a rat glioma model to evaluate and refine intra-arterial dosing parameters using Cereport. The first experiment investigated whether desensitization or tachyphylaxis to the effects of Cereport on vascular permeability can be avoided during the course of super-selective, intracarotid drug administration. Super-selective administration may be used when two different arterial branches supply a single tumor in order to ensure that enough of the drug reaches the entire tumor. In this instance, the chemotherapeutic drug is infused separately and sequentially into each branch. This procedure necessitates an infusion duration that is sufficiently long to raise concerns that tachyphylaxis to B2 receptor stimulation might occur during the Cereport infusion. To study this possibility, relative concentrations, timing, and duration of Cereport were selected to mimic those encountered during super-selective drug administration.Cereport increased the uptake of carboplatin into gliomas to a similar extent as that achieved under more conventional intra-arterial procedures, suggesting that significant tachyphylaxis was not induced. A second experiment tested several alternative dosing paradigms to determine whether a single-lumen cannula could be employed when using Cereport to enhance delivery of carboplatin into a cerebral artery. Mixing carboplatin and Cereport prior to intracarotid infusion through a single-lumen cannula did not reduce the ability of Cereport to increase the permeability of the BBTB. Equivalent effects in carboplatin uptake into a tumor were also seen when the two drugs were co-infused and their infusions sequentially alternated. Finally, Cereport pretreatment did not offer any advantage, indicating very rapid effects of Cereport on the BBTB. Collectively, these data (1) establish a range of dosing paradigms wherein Cereport significantly increases delivery of chemotherapeutic drugs via a single-lumen, arterial cannula, (2) define some of the parameters required to do so successfully, and (3) further elucidate the pharmacodynamic effects of bradykinin B2 receptor-mediated changes in permeability of the BBTB.
- 1 January 1999
- Published by Taylor & Francis in Drug Delivery
- Vol. 6 (1) , 15-21
Open AccessUse of CereportTM (RMP-7) to Increase Delivery of Carboplatin to Gliomas: Insight and Parameters for Intracarotid Infusion Via a Single-Lumen Cannula
CereportTM (RMP-7) is a selective bradykinin B receptor ago2 nist that increases the permeability of the blood-brain tumor barrier (BBTB) to increase delivery of chemotherapeutic agents to brain tumors. Two experiments were performed in a rat glioma model to evaluate and refine intra-arterial dosing parameters using Cereport. The first experiment investigated whether desensitization or tachyphylaxis to the effects of Cereport on vascular permeability can be avoided during the course of super-selective, intracarotid drug administration. Super-selective administration may be used when two different arterial branches supply a single tumor in order to ensure that enough of the drug reaches the entire tumor. In this instance, the chemotherapeutic drug is infused separately and sequentially into each branch. This procedure necessitates an infusion duration that is sufficiently long to raise concerns that tachyphylaxis to B2 receptor stimulation might occur during the Cereport infusion. To study this possibility, relative concentrations, timing, and duration of Cereport were selected to mimic those encountered during super-selective drug administration.Cereport increased the uptake of carboplatin into gliomas to a similar extent as that achieved under more conventional intra-arterial procedures, suggesting that significant tachyphylaxis was not induced. A second experiment tested several alternative dosing paradigms to determine whether a single-lumen cannula could be employed when using Cereport to enhance delivery of carboplatin into a cerebral artery. Mixing carboplatin and Cereport prior to intracarotid infusion through a single-lumen cannula did not reduce the ability of Cereport to increase the permeability of the BBTB. Equivalent effects in carboplatin uptake into a tumor were also seen when the two drugs were co-infused and their infusions sequentially alternated. Finally, Cereport pretreatment did not offer any advantage, indicating very rapid effects of Cereport on the BBTB. Collectively, these data (1) establish a range of dosing paradigms wherein Cereport significantly increases delivery of chemotherapeutic drugs via a single-lumen, arterial cannula, (2) define some of the parameters required to do so successfully, and (3) further elucidate the pharmacodynamic effects of bradykinin B2 receptor-mediated changes in permeability of the BBTB.
- 21 August 1998
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 281 (5380) , 1161-1162
Sustained Delivery of Proteins for Novel Therapeutic Products
- 21 August 1998
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 281 (5380) , 1161-1162
Sustained Delivery of Proteins for Novel Therapeutic Products
- 1 April 1998
- Published by Elsevier in Brain Research
- Vol. 790 (1-2) , 1-13
Temporal ordering of pathogenic events following transient global ischemia
- 1 April 1998
- Published by Elsevier in Brain Research
- Vol. 790 (1-2) , 1-13
Temporal ordering of pathogenic events following transient global ischemia
- 1 October 1996
- Published by Elsevier in Experimental Neurology
- Vol. 141 (2) , 214-224
Unlocking the Blood–Brain Barrier: A Role for RMP-7 in Brain Tumor Therapy
- 1 October 1996
- Published by Elsevier in Experimental Neurology
- Vol. 141 (2) , 214-224
Unlocking the Blood–Brain Barrier: A Role for RMP-7 in Brain Tumor Therapy